Tag Archive for: compass pathways
Psychedelic Business Spotlight – May 6
Business, Stock ReportsThis week in psychedelic business news: Wesana Health pivots strategy; Compass Pathways makes progress on anorexia; Completion launches psychedelic VR NFTs.
Compass Pathways Shares ‘Promising’ Data That Psilocybin May Treat Anorexia
Business, ResearchThere is currently no FDA-approved treatment for anorexia. Could psychedelics be the answer?
Kevin O’Leary Predicts These 3 Psychedelic Companies Will Merge, But Should They?
Business, NewsOur resident Psychedelic Investor James Hallifax wonders if the "Shark Tank" star's prediction makes financial sense.
5 Most Important Psychedelic Clinical Trials in 2022
ResearchHere's why we think MAPS’ second Phase 3 MDMA trial is the most important psychedelic study of 2022, and 4 more that may have huge impacts.
Psychedelic Business Spotlight – March 25
Business, Stock ReportsThis week in psychedelic business news: Filament Health scores 2nd psilocybin patent; a new psychedelics company emerges as one crumbles.
Top 5 Most Influential Psychedelic Studies
ResearchWe unpack five of the most important psychedelic studies conducted in recent years as psychedelics become mainstream medicine.
My Favorite Psychedelic Stocks: Part 1
Business, EditorialOur resident Psychedelic Investor details five companies he thinks are in strong position to win the psychedelic medicine race.
DMT Vape Pen Patent Illustrates a Big Problem in the Psychedelics Industry
BusinessProblematic patents have serious implications for the entire psychedelics industry.
Psychedelic Business Spotlight – December 17
Business, Stock ReportsThis week in psychedelic business news: Cybin steps closer to a new patent; MindMed appoints new CEO; MAPS and Wesana Health resume negotiations.
Compass Pathways Study Finds SSRI Drugs Did Not Impede Psilocybin’s Therapeutic Effect
ResearchChief Medical Officer Guy Goodwin calls study "a strong signal that COMP360 psilocybin therapy could be an adjunctive treatment to SSRI antidepressant as well as a monotherapy."